Janux Therapeutics (NASDAQ:JANX) Trading 6.9% Higher – What’s Next?

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) traded up 6.9% during mid-day trading on Wednesday . The stock traded as high as $43.79 and last traded at $44.14. 110,574 shares were traded during mid-day trading, a decline of 90% from the average session volume of 1,090,951 shares. The stock had previously closed at $41.31.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. UBS Group began coverage on Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 price objective on the stock. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. Finally, BTIG Research upped their price objective on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Janux Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $89.90.

Janux Therapeutics Price Performance

The company has a market cap of $2.07 billion, a PE ratio of -33.65 and a beta of 3.16. The company has a fifty day moving average price of $51.18 and a 200 day moving average price of $48.34.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The business had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Janux Therapeutics’s revenue for the quarter was down 82.6% compared to the same quarter last year. As a group, sell-side analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO David Alan Campbell sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $67.00, for a total value of $1,005,000.00. Following the completion of the sale, the chief executive officer now owns 242,054 shares in the company, valued at $16,217,618. The trade was a 5.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total value of $140,994.86. Following the completion of the sale, the insider now owns 82,139 shares of the company’s stock, valued at $3,473,658.31. The trade was a 3.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 86,668 shares of company stock worth $4,872,515 in the last quarter. 29.40% of the stock is owned by insiders.

Institutional Trading of Janux Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of JANX. Plato Investment Management Ltd lifted its position in Janux Therapeutics by 18.7% in the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after purchasing an additional 187 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after acquiring an additional 339 shares in the last quarter. Avanza Fonder AB bought a new position in shares of Janux Therapeutics during the fourth quarter valued at approximately $139,000. AQR Capital Management LLC bought a new position in shares of Janux Therapeutics during the second quarter valued at approximately $215,000. Finally, Chicago Capital LLC bought a new position in shares of Janux Therapeutics during the fourth quarter valued at approximately $230,000. Institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.